Feb 26, 2026 06:31AM
Feb 26, 2026 06:30AM
Jan 12, 2026 06:30AM
Jan 12, 2026 06:30AM
Dec 22, 2025 07:06AM
Dec 10, 2025 04:01PM
Dec 10, 2025 04:01PM Nuvalent Appoints Ron Squarer to Board of Directors
Nov 19, 2025 04:20PM
Nov 19, 2025 04:19PM
Nov 18, 2025 04:37AM
Nov 17, 2025 11:44AM
Nov 17, 2025 06:30AM
Nov 17, 2025 06:30AM
Nov 14, 2025 04:01PM Nuvalent schedules data release for lung cancer drug trial
Nov 14, 2025 04:01PM
Nov 4, 2025 05:13PM
Nov 4, 2025 05:12PM
Oct 30, 2025 06:30AM
Oct 24, 2025 08:29AM
Oct 18, 2025 06:00AM
Oct 15, 2025 04:08PM Stifel Starts Nuvalent (NUVL) at Buy
Sep 7, 2025 04:45AM
Aug 13, 2025 01:08PM
Aug 13, 2025 01:06PM
Aug 7, 2025 06:31AM
Aug 7, 2025 06:30AM
Jul 21, 2025 06:30AM
Jul 21, 2025 06:30AM Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC
Jun 24, 2025 06:30AM
Jun 24, 2025 06:30AM
Jun 23, 2025 04:30PM
Jun 18, 2025 04:30PM
Jun 18, 2025 04:30PM
May 8, 2025 07:31AM
Apr 29, 2025 01:11PM Nuvalent Inc (NUVL) Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor
Apr 29, 2025 01:09PM
Apr 23, 2025 10:28AM
Mar 25, 2025 05:24PM
Feb 27, 2025 06:30AM
Jan 17, 2025 06:37AM
Jan 13, 2025 06:34AM
Jan 13, 2025 06:30AM Nuvalent Details Strategy to Seek First Potential Approval in 2026 and Outlines Key Anticipated 2025 Milestones
Dec 22, 2024 04:00AM
Dec 9, 2024 06:31AM
Dec 9, 2024 06:30AM
Nov 12, 2024 06:30AM
Oct 28, 2024 08:21AM
Sep 16, 2024 08:06AM
Sep 14, 2024 05:00AM Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
Sep 13, 2024 09:54AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All